NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Imunon, Inc. (IMNN) Stock Analysis

Imunon, Inc. (IMNN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMNN

$1.19

+$0.19 (+18.41%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMNN with… →

IMNN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.03
Previous Close
$1.01
Day's Range
1.01–1.21
52-Week Range
0.96–5.10
Volume
264.61K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.01
Valuation
Market Cap
$6.68M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
5.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.84
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$14.50M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.61M
1-Year Return
−76.48%
Dividend and dates
Avg Volume
106.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMNN closed at $1.19, −76.48% over 1 year.

Imunon, Inc. (IMNN) has a market capitalization of $6.68M.

In fiscal 2025, IMNN reported revenue of $0.00.

IMNN Stock Return by Calendar Year

Imunon, Inc. (IMNN) 10-year return: what $10,000 became

1 year
$10,000 $2,352
−76.48%
5 years
$10,000 $63
−99.37%
10 years
$10,000 $4
−99.96%

If you had invested $10,000 in Imunon, Inc. (IMNN) 10 years ago, at the close on October 21, 2016, it would have been worth $4 at the close on October 21, 2026: −99.96% in total, −54.57% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−68.77%
2025−69.25%
2024+39.71%
2023−49.63%
2022−83.33%
2021−23.94%
2020−58.48%
2019+21.28%
2018−47.39%
2017−36.19%
2016 (partial year)−76.00%

As of October 21, 2026.

IMNN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$14.50M—
2024$0.00−$18.62M—
2023$0.00−$19.51M—
2022$500.00K−$35.90M−7,179.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$14.65M−$14.50M—
2024$0.00—−$19.13M−$18.62M—
2023$0.00—−$21.03M−$19.51M—
2022$500.00K—−$24.92M−$35.90M−7,179.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Imunon, Inc. (IMNN) carries a market capitalisation of $6.68M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 20 employees.

IMNN last closed at $1.19 on October 21, 2026. That is +$0.19 (+18.41%) against the previous close. Over the past 52 weeks the price has ranged from $0.96 to $5.10. The latest close sits 23.96% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $14.50M. Trailing earnings per share are −3.84.

Across the 4 fiscal years on file, revenue moves from $500.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 5.03.

The reported beta is 2.01. Annualized volatility over the trailing 10 years is 162.52%. The trailing one-year total return is −76.48%. Across 10 years the annualized return works out at −54.57%.

Growth & Income

No dividend is on file for IMNN.

So far in 2026 the total return is −68.77%. The strongest complete calendar year on file is 2024 at +39.71%; the weakest is 2022 at −83.33%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Imunon, Inc. (IMNN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Imunon, Inc. IMNN $6.68M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Imunon, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Imunon, Inc.

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Visit website →